Kite Pharma (KITE) Given Daily Media Sentiment Rating of 0.22

News articles about Kite Pharma (NASDAQ:KITE) have been trending somewhat positive on Friday, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Kite Pharma earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.7341715668319 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the media stories that may have impacted Accern Sentiment’s analysis:

Shares of Kite Pharma (NASDAQ KITE) remained flat at $$179.79 during mid-day trading on Friday. The company has a market cap of $10,280.00 and a P/E ratio of -26.06. Kite Pharma has a twelve month low of $39.82 and a twelve month high of $179.95.

TRADEMARK VIOLATION WARNING: “Kite Pharma (KITE) Given Daily Media Sentiment Rating of 0.22” was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3127731/kite-pharma-kite-given-daily-media-sentiment-rating-of-0-22.html.

Kite Pharma Company Profile

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.

Insider Buying and Selling by Quarter for Kite Pharma (NASDAQ:KITE)

Receive News & Ratings for Kite Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.